Catabasis Pharma's CAT-1004 Fast Track'd for DMD
Seeking Alpha - at Seeking Alpha - Mon Jul 06, 7:25AM CDT
CAPR: 4.03 (+0.02), BMRN: 132.88 (-0.20), RNA: 18.65 (unch), CATB: 10.62 (-0.42), SRPT: 35.94 (+1.49), PFE: 32.97 (+0.35), PTCT: 37.80 (-0.12), SMMT: 11.98 (+0.27)
EMA accepts BioMarin's MAA for drisapersen; marketing clearance possible in Q3 2016
Seeking Alpha - at Seeking Alpha - Thu Jun 25, 3:32PM CDT
CAPR: 4.03 (+0.02), RNA: 18.65 (unch), CATB: 10.62 (-0.42), PFE: 32.97 (+0.35), SRPT: 35.94 (+1.49), PTCT: 37.80 (-0.12), SMMT: 11.98 (+0.27)
Akashi Therapeutics' Duchenne MD candidate shows encouraging results in early stage study
Seeking Alpha - at Seeking Alpha - Thu Jun 18, 9:48AM CDT
CAPR: 4.03 (+0.02), BMRN: 132.88 (-0.20), RNA: 18.65 (unch), CATB: 10.62 (-0.42), SRPT: 35.94 (+1.49), PFE: 32.97 (+0.35), PTCT: 37.80 (-0.12), SMMT: 11.98 (+0.27)
Catabasis Pharma initiates Phase 1/2 study of DMD candidate
Seeking Alpha - at Seeking Alpha - Wed Jun 17, 9:45AM CDT
CAPR: 4.03 (+0.02), BMRN: 132.88 (-0.20), RNA: 18.65 (unch), CATB: 10.62 (-0.42), SRPT: 35.94 (+1.49), PFE: 32.97 (+0.35), PTCT: 37.80 (-0.12), SMMT: 11.98 (+0.27)
FDA publishes draft guidance for firms developing Duchenne muscular dystrophy drugs; current front-runners OK
Seeking Alpha - at Seeking Alpha - Tue Jun 09, 12:07PM CDT
BMRN: 132.88 (-0.20), SRPT: 35.94 (+1.49), PTCT: 37.80 (-0.12)
Capricor Therapeutics jumps on FDA OK for DMD study
Seeking Alpha - at Seeking Alpha - Mon Jun 08, 8:41AM CDT
ROSG: 2.79 (+0.03), CAPR: 4.03 (+0.02), BMRN: 132.88 (-0.20), RNA: 18.65 (unch), PFE: 32.97 (+0.35), SRPT: 35.94 (+1.49), PTCT: 37.80 (-0.12), SMMT: 11.98 (+0.27)
Sarepta to initiate rolling NDA submission for eteplirsen; shares jump 38%
Seeking Alpha - at Seeking Alpha - Tue May 19, 4:40PM CDT
ROSG: 2.79 (+0.03), CAPR: 4.03 (+0.02), BMRN: 132.88 (-0.20), RNA: 18.65 (unch), PFE: 32.97 (+0.35), SRPT: 35.94 (+1.49), PTCT: 37.80 (-0.12), SMMT: 11.98 (+0.27)
BioMarin completes rolling NDA submission for drisapersen for DMD
Seeking Alpha - at Seeking Alpha - Mon Apr 27, 9:24AM CDT
ROSG: 2.79 (+0.03), CAPR: 4.03 (+0.02), BMRN: 132.88 (-0.20), RNA: 18.65 (unch), PFE: 32.97 (+0.35), SRPT: 35.94 (+1.49), PTCT: 37.80 (-0.12), SMMT: 11.98 (+0.27)
Seeking Alpha's Biotech Weekly: Gilead Isn't Perfect, Biogen-Bass, Spring Fever, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 24, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. This week, contributors grappled with deals real and imagined, industry competition...
BIIB: 315.37 (+2.75), VRTX: 134.06 (+2.06), PRGO: 179.67 (+1.50), PFE: 32.97 (+0.35), CLDN: 1.22 (+0.02), MYL: 48.65 (+0.85), OREX: 2.44 (-0.44), JNJ: 92.93 (+0.21), NVO: 56.95 (+0.37), TNXP: 7.20 (-0.28), ALNY: 107.70 (+1.94), GILD: 109.63 (+2.38), SGEN: 45.01 (+3.43), ACHN: 7.77 (+0.04), MRK: 52.09 (-0.63), GALE: 1.70 (-0.01), JUNO: 41.58 (+1.15), SNY: 50.23 (+0.46), NBY: 0.45 (+0.01), XLRN: 33.62 (+1.44)
Santhera: the only DMD drug with a successful phase III study
Seeking Alpha - at Seeking Alpha - Thu Apr 23, 9:44AM CDT
BMRN: 132.88 (-0.20), SRPT: 35.94 (+1.49), PTCT: 37.80 (-0.12)